Treatment of Lichen Simplex Chronicus Involving Anatomically Sensitive Areas

Lichen simplex chronicus (LSC) affecting anatomically sensitive areas — including the genital region — presents a distinct management challenge: standard topical agents may be poorly tolerated at these sites, limiting conventional treatment options and requiring a carefully adapted approach.

Clinical scenario

This protocol applies to patients with LSC located at anatomically sensitive sites such as the genital region, where the use of certain topical agents is poorly tolerated. In anatomically sensitive areas such as the genital region, where topical agents may be poorly tolerated, systemic treatments may be required.

Treatment approach (partial overview)

For LSC at sensitive anatomical sites, a class of topical immunomodulators — distinct from corticosteroids — plays a central role, offering an alternative that addresses tolerability concerns in delicate skin areas.

Full regimen details, including agent selection, sequencing, and clinical decision points, are available via the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s40257-025-00979-z

In anatomically sensitive areas such as the genital region, where topical agents may be poorly tolerated, systemic treatments may be required.

Topical immunomodulators such as tacrolimus and pimecrolimus are effective for long-term management of LSC, particularly on sensitive areas including the face and genitals.

Importantly, they help avoid corticosteroid-induced side effects such as skin atrophy and striae, making them a safer option for chronic use in delicate areas.

View source ↗